DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Citigroup Upgrades Esperion Therapeutics to Buy

Citigroup analyst Joel Beatty upgrades Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Buy.

Benzinga · 03/17/2020 09:30

Citigroup analyst Joel Beatty upgrades Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Buy.